ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Longeveron Inc. (LGVN) stock surged +4.00%, trading at $1.56 on NASDAQ, up from the previous close of $1.50. The stock opened at $1.51, fluctuating between $1.51 and $1.59 in the recent session.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Employees | 25 |
Beta | 0.36 |
Sales or Revenue | $709.00K |
5Y Sales Change% | -0.757% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |